ANDA 211051, held by Teva Pharms USA. Fluoxetine Hydrochloride.
As of Nov 16, 2026, ANDA 211051 (Fluoxetine Hydrochloride), held by Teva Pharms USA, was first approved by FDA on Dec 3, 2018, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 3, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fluoxetine HydrochlorideEQ 60MG BASE ยท tablet;oral | Fluoxetine Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters